Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

Article Details

Citation

Copy to clipboard

Martinez A, Gil C, Perez DI

Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

Int J Alzheimers Dis. 2011;2011:280502. doi: 10.4061/2011/280502. Epub 2011 Jun 30.

PubMed ID

21760986 [ View in PubMed

]

Abstract

Glycogen synthase kinase 3 (GSK-3), a proline/serine protein kinase ubiquitously expressed and involved in many cellular signaling pathways, plays a key role in the pathogenesis of Alzheimer's disease (AD) being probably the link between beta-amyloid and tau pathology. A great effort has recently been done in the discovery and development of different new molecules, of synthetic and natural origin, able to inhibit this enzyme, and several kinetics mechanisms of binding have been described. The small molecule called tideglusib belonging to the thiadiazolidindione family is currently on phase IIb clinical trials for AD. The potential risks and benefits of this new kind of disease modifying drugs for the future therapy of AD are discussed in this paper.

DrugBank Data that Cites this Article

Drugs

Tideglusib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tideglusib	Glycogen synthase kinase-3 beta	Protein	Humans	Yes	Antagonist	Details